Background Chronic kidney disease and heart failure are insulin resistant states associated
with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Background The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …

Objectives The purpose of this paper was to investigate the effects of dapagliflozin in chronic
kidney disease (CKD) patients, with and without heart failure (HF). Background Patients with …

OBJECTIVE In patients with moderate to severe albuminuric kidney disease, sodium–
glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post …

Aims Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …